No Data
Neurocrine (NBIX) Receives a Hold From RBC Capital
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Neurocrine Biosciences to Participate at Investor Conferences in December
Trending Stocks Today | ZenaTech up 7.47% Post-Market
Congenital Adrenal Hyperplasia Landscape Research 2024: Comprehensive Insights About 8+ Pipeline Drugs Featuring Neurocrine Biosciences, Spruce Biosciences, Lundbeck, and HBM Alpha Therapeutics
Stifel Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $166